{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Neck&page=27",
    "query": {
      "condition": "Cancer of Neck",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 3760,
    "total_pages": 376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Neck&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Neck&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T17:40:50.230Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04210115",
      "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Gastroesophageal Junction Carcinoma (GEJC)",
        "Esophageal Adenocarcinoma (EAC)"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 703,
      "start_date": "2020-02-28",
      "completion_date": "2026-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 19,
      "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210115"
    },
    {
      "nct_id": "NCT05902520",
      "title": "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HNSCC",
        "Melanoma",
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Urogenital Cancer"
      ],
      "interventions": [
        {
          "name": "DP CD8 TIL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DP CD8 TIL KD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose IL-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AgonOx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-06-19",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05902520"
    },
    {
      "nct_id": "NCT04666688",
      "title": "LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Solid Tumor",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "LYT-200",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PureTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2020-12-11",
      "completion_date": "2024-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666688"
    },
    {
      "nct_id": "NCT00443261",
      "title": "Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-02",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00443261"
    },
    {
      "nct_id": "NCT01765673",
      "title": "The Passy Muir Swallowing Self Training Device",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oropharyngeal Dysphagia"
      ],
      "interventions": [
        {
          "name": "Vibrotactile stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "James Madison University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-01-01",
      "completion_date": "2016-02-22",
      "has_results": true,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Harrisonburg, Virginia",
      "locations": [
        {
          "city": "Harrisonburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01765673"
    },
    {
      "nct_id": "NCT00343083",
      "title": "Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Erbitux, Paclitaxel & Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2004-12",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343083"
    },
    {
      "nct_id": "NCT04164069",
      "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Colorectal Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8",
        "Stage II Colon Cancer",
        "Stage II Rectal Cancer",
        "Stage III Colon Cancer",
        "Stage III Rectal Cancer",
        "Esophageal Cancer",
        "Pancreatic Cancer",
        "Bile Duct Cancer",
        "Gastric Cancer",
        "Gall Bladder Cancer",
        "Small Bowel Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Anne Noonan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-02",
      "completion_date": "2023-06-22",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04164069"
    },
    {
      "nct_id": "NCT00444054",
      "title": "The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "Cervical Cancer",
        "Uterine Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Very low carbohydrate diet (approximately 20 grams per day)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2006-02",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00444054"
    },
    {
      "nct_id": "NCT02543476",
      "title": "SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 412,
      "start_date": "2015-09-16",
      "completion_date": "2016-11-14",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Hyattsville, Maryland + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543476"
    },
    {
      "nct_id": "NCT03360890",
      "title": "Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2018-03-26",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-17T17:40:50.230Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03360890"
    }
  ]
}